Skip to main content
SpringerLink
Log in

Barrett’s esophagus and Barrett’s carcinoma

  • Published:
Current GERD Reports

Abstract

The rise in the incidence of esophageal adenocarcinomas has raised interest in the precursor lesion Barrett’s esophagus (BE). Carcinogenesis within BE follows a sequence of histopathologic changes. Low-grade intraepithelial neoplasia is the major risk factor for progression to high-grade intraepithelial neoplasia (HG-IN) and invasive carcinoma. Other risk factors are Barrett length and prevalence and size of associated hiatal hernias. Prevention of Barrett’s carcinogenesis by medical or surgical acid suppression has not been proven effective. Chemoprevention with nonsteroidal anti-inflammatory drugs, as well as other molecular-targeted therapies, are promising and currently under investigation. Endoscopic BE ablation is experimental and accompanied by severe side effects. Endoscopic surveillance is recommended for early detection of malignant progression. When the end point of surveillance (HG-IN or carcinoma) is reached, esophagectomy is still standard treatment, although a limited surgical or endoscopic resection can be performed with lower morbidity and favorable long-term results.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Cameron AJ, Ott BJ, Payne WS: The incidence of adenocarcinoma in columnar-lined (Barrett’s) esophagus. N Engl J Med 1985, 313:857–859.

    PubMed  CAS  Google Scholar 

  2. Pohl H, Welch HG: The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005, 97:142–146.

    PubMed  Google Scholar 

  3. Devesa SS, Blot WJ, Fraumeni JF Jr: Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998, 83:2049–2053.

    Article  PubMed  CAS  Google Scholar 

  4. Werner M, Flejou JF, Hainaut P, et al.: Adenocarcinoma of the oesophagus. In World Health Organization Classification of Tumours: Pathology and Genetics—Tumours of the Digestive System. Edited by Hamilton SR, Aaltonen L. Lyon, France: IARC Press; 2000:20–25.

    Google Scholar 

  5. Sampliner RE: The Practice Parameters Committee of the American College of Gastroenterology: updated guidelines for the diagnosis, surveillance, and therapy of Barrett’s esophagus. Am J Gastroenterol 2002, 97:1888–1895.

    Article  PubMed  Google Scholar 

  6. Avidan B, Sonnenberg A, Schnell TG, et al.: Hiatal hernia size, Barrett’s length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma. Am J Gastroenterol 2002, 97:1930–1936.

    Article  PubMed  Google Scholar 

  7. Sharma P, Dent J, Armstrong D, et al.: The development and validation of an endoscopic grading system for Barrett’s esophagus: the Prague C & M criteria. Gastroenterology 2006, 131:1392–1399.

    Article  PubMed  Google Scholar 

  8. van Sandick JW, van Lanschot JB, van Felius L, et al.: Intestinal metaplasia of the esophagus or esophagogastric junction: evidence of distinct clinical, pathologic, and histochemical staining features. Am J Clin Pathol 2002, 117:117–125.

    Article  PubMed  Google Scholar 

  9. Cameron AJ, Souto EO, Smyrk TC: Small adenocarcinomas of the esophagogastric junction: association with intestinal metaplasia and dysplasia. Am J Gastroenterol 2002, 97:1375–1380.

    Article  PubMed  Google Scholar 

  10. Goldblum JR: The significance and etiology of intestinal metaplasia of the esophagogastric junction. Ann Diagn Pathol 2002, 6:67–73.

    Article  PubMed  Google Scholar 

  11. Sharma P, McQuaid K, Dent J, et al.: A critical review of the diagnosis and management of Barrett’s esophagus: the AGA Chicago Workshop. Gastroenterology 2004, 127:310–330.

    Article  PubMed  Google Scholar 

  12. Ormsby AH, Vaezi MF, Richter JE, et al.: Cytokeratin immunoreactivity patterns in the diagnosis of short-segment Barrett’s esophagus. Gastroenterology 2000, 119:683–690.

    Article  PubMed  CAS  Google Scholar 

  13. Odze R: Cytokeratin 7/20 immunostaining: Barrett’s oesophagus or gastric intestinal metaplasia? Lancet 2002, 359:1711–1713.

    Article  PubMed  Google Scholar 

  14. Glickman JN, Ormsby AH, Gramlich TL, et al.: Interinstitutional variability and effect of tissue fixative on the interpretation of a Barrett cytokeratin 7/20 immunoreactivity pattern in Barrett esophagus. Hum Pathol 2005, 36:58–65.

    Article  PubMed  CAS  Google Scholar 

  15. Sarbia M, Donner A, Franke C, Gabbert HE: Distinction between intestinal metaplasia in the cardia and in Barrett’s esophagus: the role of histology and immunohistochemistry. Hum Pathol 2004, 35:371–376.

    Article  PubMed  Google Scholar 

  16. Tharavej C, Hagen JA, Peters JH, et al.: Predictive factors of coexisting cancer in Barrett’s high-grade dysplasia. Surg Endosc 2006, 20:439–443.

    Article  PubMed  CAS  Google Scholar 

  17. von Rahden BHA, Stein HJ, Weber A, et al.: Critical Reappraisal of Current Surveillance Strategies for Barrett’s Esophagus: Analysis of a Large German Barrett’s Database. Endoscopy 2007, in press.

  18. Schlemper RJ, Riddell RH, Kato Y, et al.: The Vienna classification of gastrointestinal epithelial neoplasia. Gut 2000, 47:251–255.

    Article  PubMed  CAS  Google Scholar 

  19. Ormsby AH, Petras RE, Henricks WH, et al.: Observer variation in the diagnosis of superficial oesophageal adenocarcinoma. Gut 2002, 51:671–676.

    Article  PubMed  CAS  Google Scholar 

  20. Vaughan TL, Kristal AR, Blount PL, et al.: Nonsteroidal anti-inflammatory drug use, body mass index, and anthropometry in relation to genetic and flow cytometric abnormalities in Barrett’s esophagus. Cancer Epidemiol Biomarkers Prev 2002, 11:745–752.

    PubMed  Google Scholar 

  21. Chak A, Ochs-Balcom H, Falk G, et al.: Familiality in Barrett’s esophagus, adenocarcinoma of the esophagus, and adenocarcinoma of the gastroes ophageal junction. Cancer Epidemiol Biomarkers Prev 2006, 15:1668–1673.

    Article  PubMed  Google Scholar 

  22. Drovdlic CM, Goddard KA, Chak A, et al.: Demographic and phenotypic features of 70 families segregating Barrett’s oesophagus and oesophageal adenocarcinoma. J Med Genet 2003, 40:651–656.

    Article  PubMed  CAS  Google Scholar 

  23. Romero Y, Cameron AJ, Schaid DJ, et al.: Barrett’s esophagus: prevalence in symptomatic relatives. Am J Gastroenterol 2002, 97:1127–1132.

    Article  PubMed  Google Scholar 

  24. Gerson LB, Shetler K, Triadafilopoulos G: Prevalence of Barrett’s esophagus in asymptomatic individuals. Gastroenterology 2002, 123:461–467.

    Article  PubMed  Google Scholar 

  25. Shaheen N: Is there a “Barrett’s iceberg?”quo;. Gastroenterology 2002, 123:636–639.

    Article  PubMed  Google Scholar 

  26. Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS: Is there publication bias in the reporting of cancer risk in Barrett’s esophagus? Gastroenterology 2000, 119:333–338.

    Article  PubMed  CAS  Google Scholar 

  27. Dulai GS, Shekelle PG, Jensen DM, et al.: Dysplasia and risk of further neoplastic progression in a regional Veterans Administration Barrett’s cohort. Am J Gastroenterol 2005, 100:775–778.

    Article  PubMed  Google Scholar 

  28. Weston AP, Sharma P, Mathur S, et al.: Risk stratification of Barrett’s esophagus: updated prospective multivariate analysis. Am J Gastroenterol 2004, 99:1657–1666.

    Article  PubMed  Google Scholar 

  29. Öberg S, Wenner J, Johansson J, et al.: Barrett esophagus: risk factors for progression to dysplasia and adenocarcinoma. Ann Surg 2005, 242:49–54.

    Article  PubMed  Google Scholar 

  30. de Jonge PJ, Steyerberg EW, Kuipers EJ, et al.: Risk factors for the development of esophageal adenocarcinoma in Barrett’s esophagus. Am J Gastroenterol 2006, 101:1421–1429.

    Article  PubMed  Google Scholar 

  31. Morales CP, Souza RF, Spechler SJ: Hallmarks of cancer progression in Barrett’s oesophagus. Lancet 2002, 360:1587–1589.

    Article  PubMed  Google Scholar 

  32. Tannapfel A: Molecular findings in Barrett’s epithelium. Dig Dis 2004, 22:126–133.

    Article  PubMed  Google Scholar 

  33. Fitzgerald RC: Molecular basis of Barrett’s oesophagus and oesophageal adenocarcinoma. Gut 2006, 55:1810–1820.

    Article  PubMed  CAS  Google Scholar 

  34. Brabender J, Marjoram P, Salonga D, et al.: A multigene expression panel for the molecular diagnosis of Barrett’s esophagus and Barrett’s adenocarcinoma of the esophagus. Oncogene 2004, 23:4780–4788.

    Article  PubMed  CAS  Google Scholar 

  35. Mehta S, Johnson IT, Rhodes M: Systematic review: the chemoprevention of oesophageal adenocarcinoma. Aliment Pharmacol Ther 2005, 22:759–768.

    Article  PubMed  CAS  Google Scholar 

  36. Leedham S, Jankowski J: The evidence base of proton pump inhibitor chemopreventative agents in Barrett’s esophagus—the good, the bad, and the flawed! Am J Gastroenterol 2007, 102:21–23.

    Article  PubMed  CAS  Google Scholar 

  37. Sharma P, Sidorenko EI: Are screening and surveillance for Barrett’s oesophagus really worthwhile? Gut 2005, 54(suppl 1):i27–i32.

    Article  PubMed  Google Scholar 

  38. Eisen GM, Sandler RS, Murray S, Gottfried M: The relationship between gastroesophageal reflux disease and its complications with Barrett’s esophagus. Am J Gastroenterol 1997, 92:27–31.

    PubMed  CAS  Google Scholar 

  39. Gerson LB, Triadafilopoulos G: Screening for esophageal adenocarcinoma: an evidence-based approach. Am J Med 2002, 113:499–505.

    Article  PubMed  Google Scholar 

  40. van Blankenstein M: Barrett’s esophagus: so what! Dis Esophagus 2002, 15:1–4.

    Article  PubMed  Google Scholar 

  41. Corley DA, Levin TR, Habel LA, et al.: Surveillance and survival in Barrett’s adenocarcinomas: a population-based study. Gastroenterology 2002, 122:633–640.

    Article  PubMed  Google Scholar 

  42. Streitz JM Jr, Andrews CW Jr, Ellis EH Jr: Endoscopic surveillance of Barrett’s esophagus. Does it help? J Thorac Cardiovasc Surg 1993, 105:383–387.

    PubMed  Google Scholar 

  43. Peters JH, Clark GW, Ireland AP: Outcome of adenocarcinoma arising in Barrett’s esophagus in endoscopically surveyed and nonsurveyed patients. J Thorac Cardiovasc Surg 1994, 108:813–822.

    PubMed  CAS  Google Scholar 

  44. van Sandick JW, van Lanschot JJ, Kuiken BW, et al.: Impact of endoscopic biopsy surveillance of Barrett’s oesophagus on pathological stage and clinical outcome of Barrett’s carcinoma. Gut 1998, 43:216–222.

    Article  PubMed  Google Scholar 

  45. Heitmiller RF, Redmond M, Hamilton SR: Barrett’s esophagus with high-grade dysplasia. An indication for prophylactic esophagectomy. Ann Surg 1996, 224:66–71.

    Article  PubMed  CAS  Google Scholar 

  46. Aldulaimi DM, Cox M, Nwokolo CU, Loft DE: Barrett’s surveillance is worthwhile and detects curable cancers. A prospective cohort study addressing cancer incidence, treatment outcome and survival. Eur J Gastroenterol Hepatol 2005, 17:943–950.

    Article  PubMed  Google Scholar 

  47. Incarbone R, Bonavina L, Saino G, et al.: Outcome of esophageal adenocarcinoma detected during endoscopic biopsy surveillance for Barrett’s esophagus. Surg Endosc 2002, 16:263–266.

    Article  PubMed  CAS  Google Scholar 

  48. Parrilla P, Martinez de Haro LF, Ortiz A, et al.: Long-term results of a randomized prospective study comparing medical and surgical treatment of Barrett’s esophagus. Ann Surg 2003, 237:291–298.

    Article  PubMed  Google Scholar 

  49. Feagins LA, Zhang HY, Hormi-Carver K, et al.: Acid has antiproliferative effects in nonneoplastic Barrett’s epithelial cells. Am J Gastroenterol 2007, 102:10–20.

    Article  PubMed  CAS  Google Scholar 

  50. Garcia Rodriguez LA, Lagergren J, Lindblad M: Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK. Gut 2006, 55:1538–1544.

    Article  PubMed  CAS  Google Scholar 

  51. Vaughan TL, Dong LM, Blount PL, et al.: Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett’s oesophagus: a prospective study. Lancet Oncol 2005, 6:945–952.

    Article  PubMed  CAS  Google Scholar 

  52. Kaur BS, Triadafilopoulos G: Acid-and bile-induced PGE(2) release and hyperproliferation in Barrett’s esophagus are COX-2 and PKC-epsilon dependent. Am J Physiol Gastrointest Liver Physiol 2002, 283:G327–G334.

    PubMed  CAS  Google Scholar 

  53. Kaur BS, Khamnehei N, Iravani M, et al.: Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in Barrett’s esophagus. Gastroenterology 2002, 123:60–67.

    Article  PubMed  CAS  Google Scholar 

  54. Buttar NS, Wang KK, Leontovich O, et al.: Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett’s esophagus. Gastroenterology 2002, 122:1101–1112.

    Article  PubMed  CAS  Google Scholar 

  55. Krishnan K, Brenner DE: Prostaglandin inhibitors and the chemoprevention of noncolonic malignancy. Gastroenterol Clin North Am 2001, 30:981–1000.

    Article  PubMed  CAS  Google Scholar 

  56. Zhang F, Altorki NK, Wu YC, et al.: Duodenal reflux induces cyclooxygenase-2 in the esophageal mucosa of rats: evidence for involvement of bile acids. Gastroenterology 2001, 121:1391–1399.

    Article  PubMed  CAS  Google Scholar 

  57. Buskens CJ, Van Rees BP, Sivula A, et al.: Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus. Gastroenterology 2002, 122:1800–1807.

    Article  PubMed  CAS  Google Scholar 

  58. von Rahden BH, Stein HJ, Puhringer F, et al.: Coexpression of cyclooxygenases (COX-1, COX-2) and vascular endothelial growth factors (VEGF-A, VEGF-C) in esophageal adenocarcinoma. Cancer Res 2005, 65:5038–5044.

    Article  Google Scholar 

  59. Hur C, Nishioka NS, Gazelle GS: Cost-effectiveness of aspirin chemoprevention for Barrett’s esophagus. J Natl Cancer Inst 2004, 96:316–325.

    PubMed  CAS  Google Scholar 

  60. Conio M, Cameron AJ, Chak A, et al.: Endoscopic treatment of high-grade dysplasia and early cancer in Barrett’s oesophagus. Lancet Oncol 2005, 6:311–321.

    Article  PubMed  Google Scholar 

  61. Satodate H, Inoue H, Fukami N, et al.: Squamous reepithelialization after circum ferential endoscopic mucosal resection of superficial carcinoma arising in Barrett’s esophagus. Endoscopy 2004, 36:909–912.

    Article  PubMed  CAS  Google Scholar 

  62. van Hillegersberg R, Haringsma J, ten Kate FJ, et al.: Invasive carcinoma after endoscopic ablative therapy for high-grade dysplasia in Barrett’s oesophagus. Dig Surg 2003, 20:440–444.

    Article  PubMed  Google Scholar 

  63. Walker SJ, Selvasekar CR, Birbeck N: Mucosal ablation in Barrett’s esophagus. Dis Esophagus 2002, 15:22–29.

    Article  PubMed  CAS  Google Scholar 

  64. Ortner MA, Zumbusch K, Liebetruth J, et al.: Is topical delta-aminolevulinic acid adequate for photodynamic therapy in Barrett’s esophagus? A pilot study. Endoscopy 2002, 34:611–616.

    Article  PubMed  Google Scholar 

  65. Sharma P, Wani S, Weston AP, et al.: A randomised controlled trial of ablation of Barrett’s oesophagus with multipolar electrocoagulation versus argon plasma coagulation in combination with acid suppression: long term results. Gut 2006, 55:1233–1239.

    Article  PubMed  CAS  Google Scholar 

  66. von Rahden BHA, Stein HJ: Barrett’s esophagus with high-grade intraepithelial neoplasia: observation, ablation or resection? Eur Surg 2007, in press.

  67. Schnell TG, Sontag SJ, Chejfec G, et al.: Long-term nonsurgical management of Barrett’s esophagus with high-grade dysplasia. Gastroenterology 2001, 120:1607–1619.

    Article  PubMed  CAS  Google Scholar 

  68. Pacifico RJ, Wang KK: Nonsurgical management of Barrett’s esophagus with high-grade dysplasia. Surg Oncol Clin N Am 2002, 11:321–336.

    Article  PubMed  Google Scholar 

  69. Headrick JR, Nichols FC, Miller DL, et al.: High-grade esophageal dysplasia: long-term survival and quality of life after esophagectomy. Ann Thorac Surg 2002, 73:1697–1703.

    Article  PubMed  Google Scholar 

  70. Reid BJ, Levine DS, Longton G, et al.: Predictors of progression to cancer in Barrett’s esophagus: baseline histology and flow cytometry identify low-and high-risk patient subsets. Am J Gastroenterol 2000, 95:1669–1676.

    PubMed  CAS  Google Scholar 

  71. Stein HJ, Feith M, Müller J, et al.: Limited resection for early Barrett’s cancer. Ann Surg 2000, 232:733–742.

    Article  PubMed  CAS  Google Scholar 

  72. Banki F, Mason RJ, DeMeester SR, et al.: Vagal-sparing esophagectomy: a more physiologic alternative. Ann Surg 2002, 236:324–335.

    Article  PubMed  Google Scholar 

  73. Buttar NS, Wang KK, Lutzke LS, et al.: Combined endoscopic mucosal resection and photodynamic therapy for esophageal neoplasia within Barrett’s esophagus. Gastrointest Endosc 2001, 54:682–688.

    PubMed  CAS  Google Scholar 

  74. May A, Gossner L, Pech O, et al.: Intraepithelial high-grade neoplasia and early adenocarcinoma in short-segment Barrett’s esophagus (SSBE): curative treatment using local endoscopic treatment techniques. Endoscopy 2002, 34:604–610.

    Article  PubMed  CAS  Google Scholar 

  75. Stein HJ, Feith M, Bruecher BL, et al.: Early esophageal cancer: pattern of lymphatic spread and prognostic factors for long-term survival after surgical resection. Ann Surg 2005, 242:566–573.

    PubMed  Google Scholar 

  76. Stein HJ, von Rahden BHA, Feith M: Surgery for early stage esophageal adenocarcinoma. J Surg Oncol 2005, 92:210–217.

    Article  PubMed  CAS  Google Scholar 

  77. Siewert JR, Stein HJ, Sendler A, et al.: Esophageal cancer: clinical management. In Gastrointestinal Oncology: Principles and Practice. Edited by Kelsen DA, et al.: Philadelphia: Lippincott Williams & Wilkins; 2002:261–288.

    Google Scholar 

  78. Birkmeyer JD, Siewers AE, Finlayson EV, et al.: Hospital volume and surgical mortality in the United States. N Engl J Med 2002, 346:1128–1137.

    Article  PubMed  Google Scholar 

  79. Stein HJ, Sendler A, Fink U, Siewert JR: Multidisciplinary approach to esophageal and gastric cancer. Surg Clin North Am 2000, 80:659–682.

    Article  PubMed  CAS  Google Scholar 

  80. Lordick F, Ott K, Krause BJ, et al.: PET-Response-guided treatment of locally advanced adenocarcinoma of the esophagus and esophagogastric junction. Ann Surg 2007, In press.

  81. Hulscher JB, van Sandick JW, de Boer AG, et al.: Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 2002, 347:1662–1669.

    Article  PubMed  Google Scholar 

  82. Medical Research Council Oesophageal Cancer Working Group: Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002, 359:1727–1733.

    Article  Google Scholar 

  83. Gebski V, Burmeister B, Smithers BM, et al.: Survival benefits from neoadjuvant chemoradiotherapy in oesophageal carcinoma: a meta-analysis. Australasian Gastro-Intestinal Trials Group. Lancet Oncol 2007, 8:226–234.

    Article  PubMed  CAS  Google Scholar 

  84. Weber WA, Ott K, Becker K, et al.: Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001, 19:3058–3065.

    PubMed  CAS  Google Scholar 

  85. Flamen P, Van Cutsem E, Lerut A, et al.: Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol 2002, 13:361–368.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Paracelsus Medizinische Universität Salzburg, Müllner Hauptstraße 48, A-5020, Salzburg, Austria

    Hubert J. Stein MD

Authors
  1. Burkhard H. A. von Rahden MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hubert J. Stein MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hubert J. Stein MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

von Rahden, B.H.A., Stein, H.J. Barrett’s esophagus and Barrett’s carcinoma. Curr GERD Rep 1, 125–132 (2007). https://doi.org/10.1007/s12171-007-0008-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12171-007-0008-y

Keywords

Search

Navigation